

# Niger

Population 2015

20 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	3.8 (2.3–5.7)	19 (11–29)
Mortality (HIV+TB only)	0.37 (0.25–0.51)	1.9 (1.2–2.6)
Incidence (includes HIV+TB)	19 (12–27)	95 (62–136)
Incidence (HIV+TB only)	1 (0.65–1.5)	5.2 (3.3–7.5)
Incidence (MDR/RR-TB)**	0.71 (0–1.5)	3.6 (0–7.5)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	1.2 (0.42–2)	4.2 (0.12–8.3)	5.4 (0.54–10)
Males	1.6 (0.94–2.2)	12 (8.1–16)	14 (9–18)
Total	2.8 (1.8–3.8)	16 (12–20)	19 (12–27)

## TB case notifications, 2015

Total cases notified	10 625
Total new and relapse	10 383
- % tested with rapid diagnostics at time of diagnosis	<1%
- % with known HIV status	74%
- % pulmonary	85%
- % bacteriologically confirmed among pulmonary	85%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	55% (38–84)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.23 (0.12–0.39)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	414	5%
- on antiretroviral therapy	287	69%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			370 (18–720)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	21% (2.2–39)	
% notified tested for rifampicin resistance	<1%	76%	485
MDR/RR-TB cases tested for resistance to second-line drugs			42
Laboratory-confirmed cases		MDR/RR-TB: 45, XDR-TB: 2	
Patients started on treatment ****		MDR/RR-TB: 34, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	79%	10 815
Previously treated cases, excluding relapse, registered in 2014	63%	251
HIV-positive TB cases, all types, registered in 2014	62%	490
MDR/RR-TB cases started on second-line treatment in 2013	81%	31
XDR-TB cases started on second-line treatment in 2013		0

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	16%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	12% (11–13)

## TB financing, 2016

National TB budget (US\$ millions)	1.6
Funding source: domestic, international, 100% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015



## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)

